published Jul 10th 2017, 5:18 pm, by Anna Edney (Bloomberg) —Congress must renew a fee program that funds government review of new drugs and medical devices, but a legislative logjam over the Senate’s health-care overhaul stands in its way. Lawmakers need to sign off on the drug and device fees